EDITAS MEDICINE, INC. Interest Expense on Debt
EDITAS MEDICINE, INC. (EDIT) reported Interest Expense on Debt of $1.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebt · last filed 2026-08-05
- EDITAS MEDICINE, INC. interest expense, debt for the quarter ending 2026-06-30 was $1.06M, a 47.48% decline year-over-year.
- EDITAS MEDICINE, INC. interest expense, debt for the quarter ending 2026-03-31 was $1.07M, a 51.62% decline year-over-year.
- EDITAS MEDICINE, INC. interest expense, debt for the quarter ending 2025-12-31 was -$464.00K, a 121.19% decline year-over-year.
- EDITAS MEDICINE, INC. interest expense, debt for the quarter ending 2025-09-30 was $2.40M.
- EDITAS MEDICINE, INC. interest expense, debt for fiscal 2025 was $6.17M, a 181.78% increase from fiscal 2024.
- EDITAS MEDICINE, INC. interest expense, debt for fiscal 2024 was $2.19M.
| Period end | Interest Expense, Debt 3 month | Interest Expense, Debt 6 month | Interest Expense, Debt 9 month | Interest Expense, Debt 12 month | Interest Expense, Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.06M 10-Q · filed 2026-08-05 | $2.13M 10-Q · filed 2026-08-05 | $1.67M derived: sum of 3 quarters · filed 2026-08-05 | $4.07M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $1.07M 10-Q · filed 2026-05-05 | $608.00K derived: sum of 2 quarters · filed 2026-05-05 | $3.01M derived: sum of 3 quarters · filed 2026-05-05 | $5.03M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | -$464.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.94M derived: sum of 2 quarters · filed 2026-03-09 | $3.96M derived: sum of 3 quarters · filed 2026-08-05 | $6.17M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $2.40M 10-Q · filed 2025-11-10 | $4.42M derived: sum of 2 quarters · filed 2026-08-05 | $6.63M 10-Q · filed 2025-11-10 | $8.82M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $2.02M 10-Q · filed 2026-08-05 | $4.24M 10-Q · filed 2026-08-05 | $6.43M derived: sum of 3 quarters · filed 2026-08-05 | $6.43M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.22M 10-Q · filed 2026-05-05 | $4.41M derived: sum of 2 quarters · filed 2026-05-05 | $4.41M derived: sum of 3 quarters · filed 2026-05-05 | $4.41M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.19M derived: sum of 2 quarters · filed 2026-03-09 | $2.19M derived: sum of 3 quarters · filed 2026-03-09 | $2.19M 10-K · filed 2026-03-09 | $2.13M 10-K · filed 2025-03-05 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |